Leukemia drug shows promise against rare joint tumor
NCT ID NCT01207492
First seen Feb 28, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study tested a leukemia drug called nilotinib in 17 people with a rare joint tumor called PVNS or diffuse-type giant cell tumor that had come back or spread. The goal was to see if the drug could stop the tumor from growing. The drug works by blocking a protein that may help the tumor grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.